220 related articles for article (PubMed ID: 34725436)
21. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
23. EZH2: a novel target for cancer treatment.
Duan R; Du W; Guo W
J Hematol Oncol; 2020 Jul; 13(1):104. PubMed ID: 32723346
[TBL] [Abstract][Full Text] [Related]
24. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA FOXP4-AS1 facilitates the biological functions of hepatocellular carcinoma cells via downregulating ZC3H12D by mediating H3K27me3 through recruitment of EZH2.
Ye J; Fu Y; Wang Z; Yu J
Cell Biol Toxicol; 2022 Dec; 38(6):1047-1062. PubMed ID: 34545456
[TBL] [Abstract][Full Text] [Related]
26. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
[TBL] [Abstract][Full Text] [Related]
27. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-20a Suppresses Tumor Proliferation and Metastasis in Hepatocellular Carcinoma by Directly Targeting EZH1.
Zhang Q; Deng X; Tang X; You Y; Mei M; Liu D; Gui L; Cai Y; Xin X; He X; Huang J
Front Oncol; 2021; 11():737986. PubMed ID: 34976797
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
30. Maternal Ezh1/2 deficiency in oocyte delays H3K27me2/3 restoration and impairs epiblast development responsible for embryonic sub-lethality in mouse.
Zhao Y; Bai D; Wu Y; Zhang D; Liu M; Tian Y; Lu J; Wang H; Gao S; Lu Z
Development; 2022 Aug; 149(15):. PubMed ID: 35796552
[TBL] [Abstract][Full Text] [Related]
31. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
[TBL] [Abstract][Full Text] [Related]
32. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
33. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.
Lee YY; Mok MT; Kang W; Yang W; Tang W; Wu F; Xu L; Yan M; Yu Z; Lee SD; Tong JHM; Cheung YS; Lai PBS; Yu DY; Wang Q; Wong GLH; Chan AM; Yip KY; To KF; Cheng ASL
Nucleic Acids Res; 2018 Sep; 46(17):8832-8847. PubMed ID: 29992318
[TBL] [Abstract][Full Text] [Related]
34. The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration.
Bae WK; Kang K; Yu JH; Yoo KH; Factor VM; Kaji K; Matter M; Thorgeirsson S; Hennighausen L
FASEB J; 2015 May; 29(5):1653-62. PubMed ID: 25477280
[TBL] [Abstract][Full Text] [Related]
35. Targeting EZH2 in cancer.
Kim KH; Roberts CW
Nat Med; 2016 Feb; 22(2):128-34. PubMed ID: 26845405
[TBL] [Abstract][Full Text] [Related]
36. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
37. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
[TBL] [Abstract][Full Text] [Related]
38. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Ezh2 In Vitro and the Decline of
Hong F; Zhao M; Zhang L; Feng L
Stem Cells Dev; 2019 May; 28(10):649-658. PubMed ID: 30887911
[TBL] [Abstract][Full Text] [Related]
40. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
